In this Tuesday, July 30, 2013, photo, people walk along a corridor at the headquarters of Johnson & Johnson in New Brunswick, N.J. A panel of Food and Drug Administration experts again rejected Johnson & Johnson's bid on Thursday, Jan. 16, 2014, to expand use of its blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease. (AP Photo/Mel Evans)